Australian and US study groups have claimed that they have found that melanoma has counteracted in a totally different manner, and shows resistance towards a promising experimental cancer pill called PLX4032.

The researchers stated that the study might help to fight the deadly skin cancer.

The study was spearheaded by the study group at the University of California, Los Angeles (UCLA), and at the same time comprising of the Peter MacCallum Cancer Center in Melbourne, it was found that two entirely different resistance mechanisms state that melanoma provides resistance to the cure related with PLX4032.

Another team working on the same lines at the Broad Institute, Massachusetts, discovered the stats to be near to one third of it.

These findings were released in the journal Nature. PLX4032 comprises of a totally new class of drug that targets tumour cells with a mutation found in a gene called BRAF.

A protein, synthesized by the BRAF gene, aides in releasing signals which aides in cellular growth. When BRAF gene mutates it might affect the operation of the protein, resulting in varied form of cancers including melanoma. The mutation is said to occur only in case of 50% to 60% of melanoma patients.